Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Skylight Health Group (SLHG) provided an update on the status of its research program, Skylight Health Research
  • Skylight Health Research has been awarded 11 clinical studies and four are ongoing
  • Total revenue earned through clinical studies in 2021 was $300,000, which has more than doubled in 2022
  • Skylight recently announced two new partnerships with Elligo Health Research and Endominance
  • Skylight Health Group Inc. (SLHG) is up 12.82 per cent trading at C$0.88 per share at 10:05 am ET

Skylight Health Group (SLHG) provided an update on the status of its research program, Skylight Health Research.

Formally launched in 2021, Skylight Health Research has been awarded 11 clinical studies and four are currently ongoing at three clinics. The newest study awarded will be conducted at three clinics launching in September 2022. 

Total revenue earned through clinical studies in 2021 was $300,000, which has more than doubled in 2022 so far.

Skylight recently announced two new partnerships with Elligo Health Research and Endominance.

Skylight Health Research officially joined Elligo’s clinical research network in 2022 and has been working to fully onboard all five clinics participating in Elligo’s Research Ready program.

The Endominance partnership involves their Microbiome, Anxiety, & Cognitive Orientation (MACO) study to assist with patient recruitment. The purpose of the MACO study is to better understand how gut bacteria may affect the brain and how they may be associated with anxious human behaviour and cognitive traits.

Skylight’s VP of Clinical Research, Alisha Garibaldi called this a fitting and seamless partnership.

“The relationship between the microbiome and mental health has become a much more common topic lately, and the MACO study is investigating this complex relationship on a very large scale. We’re excited to work with Endominance on a study that aligns so closely with Skylight’s values and drive to contribute to the advancement of medical science.”

Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health, and laboratory/diagnostic testing.

Skylight Health Group Inc. (SLHG) is up 12.82 per cent trading at C$0.88 per share at 10:05 am ET.


More From The Market Herald

" Oncolytics Biotech (TSX:ONC) advances Chinese cancer trial

Oncolytics Biotech (ONC) partner, Adlai Nortye, reported results from a clinical evaluation of pelareorep-paclitaxel combination therapy for advanced breast cancer.

" MCI Onehealth (TSX:DRDR) clinical data insights pipeline gains momentum

MCI Onehealth (DRDR) is evolving its tech and clinical data insights through revenue deals and relationships with businesses in health and life-sciences.

" BriaCell (TSX:BCT) releases positive clinical and quality of life data in advanced metastatic breast cancer study

BriaCell Therapeutics (BCT) presented positive safety/tolerability and efficacy data from its lead product candidate, Bria-IMT.

" Sirona Biochem (TSXV:SBM) begins clinical trial for anti-aging compound TFC-1326

Sirona Biochem Corp. (SBM) has begun the clinical trial for its novel anti-aging compound TFC-1326.